GlobeNewswire All Public CompaniesCodex · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 20:05:00·⟳ 抓取 20:06:54·⚡ 决策 08-27 20:34:29 +27m35s·60.9 天前
Harmony Biosciences 将参加 Cantor 全球医疗会议炉边谈话
本条为公司例行投资者会议参会公告，未提供会改变收入、利润、管线、监管状态或资本结构的新增事实，不能形成正期望交易。
📄 原文GlobeNewswire All Public Companies↗ 原文
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today annou…
不做 Harmony Biosciences Holdings, Inc.（HRMY.US）
例行投资者会议参会公告，没有新增业绩、监管、管线或资本结构事实，缺少可交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件只说明 Harmony Biosciences 管理层将在 Cantor 医疗会议进行炉边谈话并提供 webcast；这类参会通知本身不是新订单、业绩、监管审批或产品商业化进展，也没有披露任何量级信息，因此对 Harmony Biosciences（HRMY.US）短线方向为中性，研究结论为不做。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
主要风险
- 会议中未来可能出现增量表述，但当前公告本身未披露，不能提前交易。
先例如何影响了这次决策
对本次决策的影响:先例不足且事件本身无增量，最终维持 AVOID。
方向:例行投资者会议参会公告通常缺少可交易方向，需等待会议实质内容。
涨幅量级:无可用于校准涨跌幅的高相似增量先例。
形态:当前事件无实质催化，不适合用价格先例放大交易信号。
原文全文
展开原文 · 1,463 字
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at
https://ir.harmonybiosciences.com/
.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
www.harmonybiosciences.com
.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at
https://ir.harmonybiosciences.com/
.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
www.harmonybiosciences.com
.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。